Understand this story
On October 28, 2026, MoleculeMind released a technical report on MMDesign, an AI platform for de novo protein design. The report covers 18 targets and 19 design projects across two modalities, nanobodies and macrocyclic peptides, of which 18 yielded bindable molecules, for a project success rate of 94.7%; of 453 tested candidates, 139 were confirmed to bind, for a candidate hit rate of 30.7%. For the six GPCR targets CCR7, CCR8, EP2, GPR68, NK3R, and A2AR, the report states that experimentally confirmed binding molecules were obtained for all of them, with hit rates per target ranging from 12.1% to 100%, and the best binding molecules all achieved nanomolar affinity. The report also shows that MMFold achieved a Top-1 high-quality success rate of 39.0% in 172 interface evaluations of antibody-antigen complex structure prediction in FoldBench, compared with 19.8% for AlphaFold 3.
AI-generated from public reports
Latest development · Report
MoleculeMind MMDesign Technical Report: 18 of 19 Projects Succeeded, All 6 GPCR Targets HitDevelopments
1 confirmed developments
- Source:English text is being prepared.
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Oct 28
QbitAI
MoleculeMind MMDesign Technical Report: 18 of 19 Projects Succeeded, All 6 GPCR Targets Hit
MoleculeMind has released a technical report on its AI de novo protein design platform MMDesign, covering 19 design projects across 18 targets and two modalities—nanobodies and macrocyclic peptides—of which 18 yielded bindable molecules, for a project success rate of 94.7%; among 453 tested candidates, 139 were confirmed to bind, for a candidate hit rate of 30.7%. For all six GPCR targets CCR7, CCR8, EP2, GPR68, NK3R, and A2AR, experimentally confirmed binding molecules were obtained, with per-target hit rates ranging from 12.1% to 100%, and the best binding molecules all achieved nanomolar affinity. The report also shows that MMFold achieved a Top-1 high-quality success rate of 39.0% in 172 interface evaluations of antibody-antigen complex structure prediction in FoldBench, compared with 19.8% for AlphaFold 3.
Phoenix Technology
MoleculeMind MMDesign Technical Report: 18 of 19 Projects Successful, All 6 GPCR Targets Hit
MoleculeMind has released a technical report on its AI protein de novo design platform MMDesign, covering 19 projects across 18 targets and two modalities—nanobodies and macrocyclic peptides—with 18 yielding experimentally confirmed binders, a project success rate of 94.7%; of 453 tested candidates, 139 were hits, a candidate hit rate of 30.7%. All six GPCR targets succeeded, with best affinities reaching the nanomolar level: GPR68 achieved a best KD as low as 12.1 nM, and all 30 candidates for NK3R were confirmed to bind. The report also shows that when redesigning against 6 targets that already had binders, 5 achieved improvements, and it presents results for the structure prediction model MMFold on the FoldBench antibody–antigen interface benchmark.